High-risk symptoms do not predict gastric cancer precursors.


Journal

Helicobacter
ISSN: 1523-5378
Titre abrégé: Helicobacter
Pays: England
ID NLM: 9605411

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 09 04 2018
revised: 06 08 2018
accepted: 07 09 2018
pubmed: 10 11 2018
medline: 25 4 2019
entrez: 10 11 2018
Statut: ppublish

Résumé

Gastric intestinal metaplasia (GIM) is the most common precursor of gastric cancer. Our aim is to determine if presenting symptoms predict gastric cancer precursor lesions in a high-risk population. Consecutive unique patients evaluated by endoscopy for upper gastrointestinal symptoms at the Los Angeles County Hospital between 2010 and 2014 were evaluated. Presenting symptoms were classified as low- or high-risk depending on the procedure indication as coded using the Clinical Outcomes Research Initiative (CORI) system. Endoscopy and histology results were used to classify findings as benign, GIM, high-risk GIM, or malignant. The primary outcome was the proportion of patients with premalignant or malignant gastric findings who had high-risk clinical indications for endoscopy relative to those with benign results. A total of 3699 patients underwent endoscopy to evaluate upper gastrointestinal symptoms. There were 373 (10.1%) patients with GIM of which 278 had high-risk GIM. One hundred and sixty (4.3%) patients were diagnosed with gastric cancer. High-risk indications for upper endoscopy predicted gastric cancer (OR 1.8 [95% CI 1.3-2.6]) but not GIM (OR 1.0 [0.8-1.3]) or high-risk GIM (OR 0.9 [0.7-1.2]). Hispanic or Asian patients and patients >50 years old were more likely to have GIM, high-risk GIM, and cancer. Performance of upper endoscopy for high-risk indications is inadequate to detect GIM and marginal for malignancy. At risk patients should undergo upper endoscopy for both low- and high-risk symptoms. Screening certain populations deserve additional study and may, in fact, be cost-effective.

Sections du résumé

BACKGROUND & STUDY AIMS OBJECTIVE
Gastric intestinal metaplasia (GIM) is the most common precursor of gastric cancer. Our aim is to determine if presenting symptoms predict gastric cancer precursor lesions in a high-risk population.
PATIENT AND METHODS METHODS
Consecutive unique patients evaluated by endoscopy for upper gastrointestinal symptoms at the Los Angeles County Hospital between 2010 and 2014 were evaluated. Presenting symptoms were classified as low- or high-risk depending on the procedure indication as coded using the Clinical Outcomes Research Initiative (CORI) system. Endoscopy and histology results were used to classify findings as benign, GIM, high-risk GIM, or malignant. The primary outcome was the proportion of patients with premalignant or malignant gastric findings who had high-risk clinical indications for endoscopy relative to those with benign results.
RESULTS RESULTS
A total of 3699 patients underwent endoscopy to evaluate upper gastrointestinal symptoms. There were 373 (10.1%) patients with GIM of which 278 had high-risk GIM. One hundred and sixty (4.3%) patients were diagnosed with gastric cancer. High-risk indications for upper endoscopy predicted gastric cancer (OR 1.8 [95% CI 1.3-2.6]) but not GIM (OR 1.0 [0.8-1.3]) or high-risk GIM (OR 0.9 [0.7-1.2]). Hispanic or Asian patients and patients >50 years old were more likely to have GIM, high-risk GIM, and cancer.
CONCLUSIONS CONCLUSIONS
Performance of upper endoscopy for high-risk indications is inadequate to detect GIM and marginal for malignancy. At risk patients should undergo upper endoscopy for both low- and high-risk symptoms. Screening certain populations deserve additional study and may, in fact, be cost-effective.

Identifiants

pubmed: 30412322
doi: 10.1111/hel.12548
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12548

Subventions

Organisme : NIH/NCRR SC CTSI
ID : UL1TR000130

Informations de copyright

© 2018 John Wiley & Sons Ltd.

Auteurs

Ben Da (B)

Digestive Disease Branch, National Institutes of Health, Bethesda, Maryland.

Niraj Jani (N)

Division of Gastroenterology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Nikhil Gupta (N)

Division of Gastroenterology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Preeth Jayaram (P)

Division of Gastroenterology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Ravi Kankotia (R)

Division of Gastroenterology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Chung Yao Yu (C)

Division of Gastroenterology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Mario Dinis-Ribeiro (M)

Department of Gastroenterology, Portuguese Oncology Institute, Porto, Portugal.

James Buxbaum (J)

Division of Gastroenterology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH